Accellta Overview
Accellta specializes in large-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. These products are used in cell banking, drug discovery, regenerative medicine, and scientific research. The company uses 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions, optimizing production efficiency and reducing costs while maintaining consistent quality. Accellta's manufacturing facility adheres to Good Manufacturing Practice (GMP) guidelines, supporting industrial-scale cell banking and clinical batch production. The company’s patent portfolio covers media formulations and pluripotent stem cell culturing techniques, reflecting its focus on advancing cell culture technologies.
Cumulative Funding Raised Over Time ($)
—Nov 2012
—Nov 2014
Latest News
growth-positive
Hitachi Chemical licenses stem cell tech from Israel's Accellta
Japanese company Hitachi Chemical has signed a Technical License Agreement with Accellta, a Haifa-based company that develops culture media and methods for stem cell production. Accelltas technologies aim to accelerate the use of stem cells for clinical and regenerative applications. The company has received investments from AMIT and Horizon Ventures. Hitachi Chemical, which recently acquired a US-based company in the regenerative medicine market, will utilize Accelltas stem cell culture media and methods to strengthen its technological capabilities in contracted cell manufacturing. Accellta also has agreements with Thermo Fisher and other companies and is considering a merger or IPO in the future.
PartnersInvestmentAcquisitionPublic Trading
growth-positive
Accellta CEO says israeli stem cell specialist seeks global partners
Accellta CEO Itzchak Angel discusses the companys stem cell culturing process and future expansion plans, including a planned USD 15 million capital-raising exercise and the search for corporate partners. The potential applications of Accelltas technologies include cell-based medical therapies, research tools, drug screening and development, and tissue engineering.
InvestmentPartners
growth-positive
Nano Dimension and Accellta Joined Forces to Successfully BioPrint Stem Cell-Derived Tissues
Nano Dimension has successfully lab-tested a proof of concept 3D Bioprinter for stem cells in collaboration with Accellta Ltd. The trial confirmed that the companies technologies enabled printing of viable stem cells using an adapted 3D printer. The companies are considering the formation of a new entity for future solutions. The market for 3D bioprinting is expected to grow rapidly, and Nano Dimensions advanced inkjet technology may pave the way for advanced multi-material printing domains. Nano Dimension focuses on the development of advanced 3D printed electronics systems and nanomaterials. Accellta specializes in innovative media and technologies for culturing and differentiating human stem cells.
Partners
growth-positive
Cellect Announces the Signing of a Collaboration Agreement with Accellta
Cellect Biomed has signed a collaboration agreement with Accellta, a leading Israeli stem cell company. Accellta will have a nonexclusive right to evaluate the impact of Cellects apoptotic induction based technology on its stem cell culturing technologies. The collaboration aims to grow Accelltas pluripotent cells safely and in a shorter time using Cellects technology. The potential market for these applications is estimated at billions of dollars. Accellta will pay Cellect approximately NIS300,000 for the limited right to test the technology. The evaluation stage will last several months, and if successful, the companies will negotiate the terms of a full license. Cellects business model focuses on developing its own products for medical applications and granting licenses for its technology to other companies and research institutions in the stem cell field.
Partners
Growth-Positive
Accellta Grants Rights for its Feeder-free Stem Cell Culture Medium to Thermo Fisher Scientific
Stem cell company Accellta has granted worldwide non-exclusive rights to Thermo Fisher Scientific for the manufacture and distribution of its proprietary cell culture medium and ancillary products and methods. Accelltas patented technology is designed to enable homogeneous growth of stem cell production by enabling culturing of the cells in feeder-free, serum-free and xeno-free media. The company is currently focused on creating strategic partnerships with biopharma and stem cell companies for developing large-scale and cost-effective tailor-made manufacturing processes for cell products.
PartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $500K |
| Last funding | $500K |
| Stage | Mature |
| Rounds | 3 |
| Investors | 2 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | accellta.com |
Locations
Haifa, Israel
Photos & Videos
3 item(s)
Accellta Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Agriculture & FoodProcessed FoodsBeveragesHealthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersLaboratoriesIndustrial ManufacturingManufacturing FacilitiesCore Technology
BiologicalsCellsTags (14)
foodtechregenerative-medicinebiotechnologymedical-technologiesstem-cellsbioprocesslaboratories3d-technologydrug-discoverypharma-companieshealthcare-providersfood-and-beveragemanufacturing-facilitiesclinicsGeographic Markets
GlobalEuropeAmericasAsiaAccellta Financials
$500K
Total funding
Undisclosed
Capital raised
$500K
Last funding
Mature
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
—Nov 2012
—Nov 2014
Private Equity Funding
A Round
Nov 2014
Undisclosed
AMIT-Technion ( The Alfred Mann Institute), Horizons Ventures
Seed
Nov 2012
Undisclosed
AMIT-Technion ( The Alfred Mann Institute)
Non-Equity Funding
GrantEvent
Jan 2024
$500K
Israel Innovation Authority
Accellta Lifecycle
Cumulative Funding Raised Over Time
—Nov 2012
—Nov 2014
All Events
A Round
Nov 2014
Undisclosed
AMIT-Technion ( The Alfred Mann Institute), Horizons Ventures
Seed
Nov 2012
Undisclosed
AMIT-Technion ( The Alfred Mann Institute)
GrantEvent
Jan 2024
$500K
Israel Innovation Authority
Accellta News
7 articles
growth-positive
Hitachi Chemical licenses stem cell tech from Israel's Accellta
Japanese company Hitachi Chemical has signed a Technical License Agreement with Accellta, a Haifa-based company that develops culture media and methods for stem cell production. Accelltas technologies aim to accelerate the use of stem cells for clinical and regenerative applications. The company has received investments from AMIT and Horizon Ventures. Hitachi Chemical, which recently acquired a US-based company in the regenerative medicine market, will utilize Accelltas stem cell culture media and methods to strengthen its technological capabilities in contracted cell manufacturing. Accellta also has agreements with Thermo Fisher and other companies and is considering a merger or IPO in the future.
PartnersInvestmentAcquisitionPublic Trading
growth-positive
Accellta CEO says israeli stem cell specialist seeks global partners
Accellta CEO Itzchak Angel discusses the companys stem cell culturing process and future expansion plans, including a planned USD 15 million capital-raising exercise and the search for corporate partners. The potential applications of Accelltas technologies include cell-based medical therapies, research tools, drug screening and development, and tissue engineering.
InvestmentPartners
growth-positive
Nano Dimension and Accellta Joined Forces to Successfully BioPrint Stem Cell-Derived Tissues
Nano Dimension has successfully lab-tested a proof of concept 3D Bioprinter for stem cells in collaboration with Accellta Ltd. The trial confirmed that the companies technologies enabled printing of viable stem cells using an adapted 3D printer. The companies are considering the formation of a new entity for future solutions. The market for 3D bioprinting is expected to grow rapidly, and Nano Dimensions advanced inkjet technology may pave the way for advanced multi-material printing domains. Nano Dimension focuses on the development of advanced 3D printed electronics systems and nanomaterials. Accellta specializes in innovative media and technologies for culturing and differentiating human stem cells.
Partners
growth-positive
Cellect Announces the Signing of a Collaboration Agreement with Accellta
Cellect Biomed has signed a collaboration agreement with Accellta, a leading Israeli stem cell company. Accellta will have a nonexclusive right to evaluate the impact of Cellects apoptotic induction based technology on its stem cell culturing technologies. The collaboration aims to grow Accelltas pluripotent cells safely and in a shorter time using Cellects technology. The potential market for these applications is estimated at billions of dollars. Accellta will pay Cellect approximately NIS300,000 for the limited right to test the technology. The evaluation stage will last several months, and if successful, the companies will negotiate the terms of a full license. Cellects business model focuses on developing its own products for medical applications and granting licenses for its technology to other companies and research institutions in the stem cell field.
Partners
Growth-Positive
Accellta Grants Rights for its Feeder-free Stem Cell Culture Medium to Thermo Fisher Scientific
Stem cell company Accellta has granted worldwide non-exclusive rights to Thermo Fisher Scientific for the manufacture and distribution of its proprietary cell culture medium and ancillary products and methods. Accelltas patented technology is designed to enable homogeneous growth of stem cell production by enabling culturing of the cells in feeder-free, serum-free and xeno-free media. The company is currently focused on creating strategic partnerships with biopharma and stem cell companies for developing large-scale and cost-effective tailor-made manufacturing processes for cell products.
PartnersExpand
growth-positive
Accelta signs collaboration with Stemcell Technologies
Israeli stem cell company Accelta has signed an exclusive agreement with Stemcell Technologies to market its culturing solution for growing stem cells. Accelta has completed a seed round with participation from AMIT, Horizon Ventures, and Rambam Hospital. The companys products allow for the growth of stem cells without using feeders, animal products, or adhesive surfaces, which significantly lowers the cost. The partnership with Stemcell Technologies is expected to maximize the global accessibility of Acceltas solutions.
Partners
First Licensing Deals for Stem Cell Company Accellta
Accellta Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 17 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 18 classification IDs that could be used for matching.
Accellta Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514840446 |
| Crunchbase | accellta |
| Phone | 0549885551|+972 54 9885551 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-29T00:00:00.000Z |
| Created | 2015-01-06T00:00:00.000Z |
| Claimed | Yes |